Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial

BACKGROUND: To explore the effect of abatacept treatment on patient-reported outcomes (PROs) in psoriatic arthritis (PsA). METHODS: Patients with PsA were randomised (1:1) to subcutaneous abatacept 125 mg weekly/placebo for 24 weeks with early escape (EE) to open-label abatacept (week 16). Adjusted...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Arthritis Res Ther
Glavni autori: Strand, Vibeke, Alemao, Evo, Lehman, Thomas, Johnsen, Alyssa, Banerjee, Subhashis, Ahmad, Harris A., Mease, Philip J.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2018
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6282264/
https://ncbi.nlm.nih.gov/pubmed/30522501
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-018-1769-7
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items